This review examines the effect of temporary mechanical circulatory support on cardiogenic shock, indicating potential improvements in survival rates.
Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) remains a critical clinical challenge associated with high morbidity and mortality. Temporary mechanical circulatory support (tMCS) devices can stabilize hemodynamics, improve cardiac output, and enhance survival, thereby continuing to be more favorable with operators. This review summarizes the pathophysiology of AMI-CS and examines the evidence informing recommendations for tMCS device implementation-specifically the intra-aortic balloon pump, Impella (Abiomed/J&J MedTech), TandemHeart™ (LivaNova, Inc.), and venoarterial extracorporeal membrane oxygenation-with a particular focus on clinical trial data and recent guideline recommendations to assist operators in implementing decision-making.
No takes yet. Share an insight, caveat, or question.
Erdem et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: